New way to deliver chemo may boost survival in stomach cancer patients

NCT ID NCT07304271

Recruiting now Disease control Sponsor: Magnus Nilsson Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether giving chemotherapy directly into the abdomen (intraperitoneal paclitaxel) along with standard systemic therapy improves survival compared to systemic therapy alone in stomach cancer patients whose cancer has spread to the lining of the abdomen. About 262 participants will be randomly assigned to one of the two groups. The study is currently recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Paclitaxel given directly into the abdomen (intraperitoneal)
What this could lead to: If it works, this could offer a new first-line treatment option that improves survival for gastric cancer patients with peritoneal spread.
What could go wrong: This is a phase 3 trial, but the benefit is uncertain. The added intraperitoneal treatment may cause side effects or not improve survival enough to change practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTRIC ADENOCARCINOMA WITH PERITONEAL METASTASES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastric adenocarcinoma gastric neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GASTRIC CANCER PERITONEAL METASTASES

Contacts and locations

Locations

Amsterdam University Medical Center
NOT_YET_RECRUITING

Amsterdam, 1081, Netherlands
Azienda Ospedaliera Universitaria Integrata Verona
NOT_YET_RECRUITING

Verona, 37126, Italy
Karolinska University Hospital
RECRUITING

Stockholm, 171 76, Sweden
Sahlgrenska University Hospital
NOT_YET_RECRUITING

Gothenburg, 413 46, Sweden
Skane University Hospital
NOT_YET_RECRUITING

Lund, SE-222 42, Sweden
Uppsala University Hospital
RECRUITING

Uppsala, SE-751 85, Sweden
Örebro University Hospital
NOT_YET_RECRUITING

Örebro, SE-701 85, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.